Holen Sie sich die Stockscreener-App
1.20
4.40%
-0.05
Schlusskurs vom Vortag:
$1.25
Offen:
$1.26
24-Stunden-Volumen:
428.14K
Relative Volume:
0.54
Marktkapitalisierung:
$72.12M
Einnahmen:
$10.33M
Nettoeinkommen (Verlust:
$-129.77M
KGV:
-1.2001
EPS:
-0.9999
Netto-Cashflow:
$-140.33M
1W Leistung:
+3.02%
1M Leistung:
+11.68%
6M Leistung:
+9.63%
1J Leistung:
-12.13%
1-Tages-Spanne:
$1.1627
$1.29
1-Wochen-Bereich:
$1.1372
$1.29
52-Wochen-Spanne:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.20 | 75.13M | 10.33M | -129.77M | -140.33M | -0.9999 |
VRTX
Vertex Pharmaceuticals Inc
|
426.27 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
713.28 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.74 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.39 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.67 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
TScan Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
TScan Therapeutics Announces Q1 2026 Financial Results, Phase 3 TSC-101 Trial Launch, and Pipeline Updates - Minichart
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
TScan Therapeutics Reports $175.3 Million in Cash Reserves, Funding Operations Into Second Half of 2028 - geneonline.com
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance UK
Is TScan Therapeutics (TCRX) stock worth taking a position in - Newser
TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting - Sahm
TCRX Financials: Income Statement, Balance Sheet & Cash Flow | Tscan Therapeutics, Inc. - Stock Titan
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics (NASDAQ: TCRX) seeks big boost in authorized shares at 2026 meeting - Stock Titan
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TCRX: TCR T cell therapy shows >50% relapse reduction in AML/MDS, pivotal trial starts mid-2024 - TradingView
TCRX: TCR T cell therapy halves relapse rates in AML/MDS, with pivotal trial and expansion planned - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts - MarketBeat
H.C. Wainwright reiterates Buy on Tscan stock, $7 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Tscan stock, $7 target - Investing.com
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Sahm
TScan Therapeutics (NASDAQ: TCRX) seeks approval to double authorized shares to 600M - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3%Here's What Happened - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3% – Here’s What Happened - Defense World
Market Recap: Will TScan Therapeutics Inc stock benefit from M A2026 Technical Overview & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Will TScan Therapeutics (TCRX) Stock Recover Soon | Price at $1.06, Up 5.45%Most Watched Stocks - Newser
TCRX Stock Analysis: TScan Therapeutics Inc. Biotech at $1 Level Following Small Daily Dip - Newser
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation - TipRanks
TScan Therapeutics announces resignation of vice president of finance - Investing.com UK
TScan Therapeutics announces resignation of vice president of finance By Investing.com - Investing.com Australia
TScan Therapeutics (TCRX) CFO adds principal accounting officer role after VP finance resignation - Stock Titan
TCRX Technical Analysis & Stock Price Forecast - Intellectia AI
TCRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Strong analyst sentiment on TScan Therapeutics (TCRX) amid ongoing momentum in cell therapy space - MSN
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Yahoo Finance
Earnings Risk: Will TScan Therapeutics Inc stock benefit from M A2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
Top 10 Stocks Under $5 That Could Triple - Insider Monkey
Aug Catalysts: Will TScan Therapeutics Inc outperform its industry peersQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Retail Trends: What is the implied volatility of TScan Therapeutics Inc2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
How does TScan Therapeutics Inc score in quality rankings2026 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Risk Check: Will TScan Therapeutics Inc outperform its industry peersMarket Sentiment Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Geopolitics Watch: Is TScan Therapeutics Inc. stock risky to hold now2026 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TCRXTscan Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00 - Defense World
What are the risks of holding TScan Therapeutics Inc2025 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
| Lynx1 Capital Management LP | 10% Owner |
May 19 '25 |
Buy |
1.20 |
1,388,794 |
1,666,553 |
6,746,141 |
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
5.78%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):